These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33519217)

  • 61. Utilization and Treatment Patterns of Disease-Modifying Therapy in Pediatric Patients with Multiple Sclerosis in the United States.
    Greenberg B; Kolodny S; Wang M; Deshpande C
    Int J MS Care; 2021; 23(3):101-105. PubMed ID: 34177381
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The impact of treatment adherence on clinical and economic outcomes in multiple sclerosis: Real world evidence from Alberta, Canada.
    Gerber B; Cowling T; Chen G; Yeung M; Duquette P; Haddad P
    Mult Scler Relat Disord; 2017 Nov; 18():218-224. PubMed ID: 29141814
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
    Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H
    J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis.
    Thomas NP; Curkendall S; Farr AM; Yu E; Hurley D
    J Med Econ; 2016; 19(5):497-505. PubMed ID: 26706292
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
    Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
    J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cost Sharing of Disease-Modifying Treatments (DMTs) as Policy Lever to Improve DMTs' Access in Multiple Sclerosis.
    Shao H; Stoecker C; Monnette AM; Shi L
    Value Health; 2018 Sep; 21(9):1083-1089. PubMed ID: 30224113
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis.
    Hellwig K; Verdun di Cantogno E; Sabidó M
    Ther Adv Neurol Disord; 2021; 14():17562864211051012. PubMed ID: 34876925
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database.
    Kawachi I; Okamoto S; Sakamoto M; Ohta H; Nakamura Y; Iwasaki K; Yoshida M; Hiroi S; Ogino M
    BMC Neurol; 2019 Dec; 19(1):324. PubMed ID: 31842786
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Health care services and disease modifying therapies use in community-based multiple sclerosis patients: Evolution from 2013 to 2015 and demographic characteristics.
    Ha-Vinh P; Nauleau S; Clementz M; Régnard P; Sauze L; Clavaud H
    Presse Med; 2019 Jan; 48(1 Pt 1):e1-e19. PubMed ID: 30528148
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.
    Simacek KF; Ko JJ; Moreton D; Varga S; Johnson K; Katic BJ
    J Med Internet Res; 2018 Oct; 20(10):e11168. PubMed ID: 30377144
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study.
    Al-Sakran L; Marrie RA; Blackburn D; Knox K; Evans C
    BMJ Open; 2019 Nov; 9(11):e033599. PubMed ID: 31772108
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature.
    Lizán L; Comellas M; Paz S; Poveda JL; Meletiche DM; Polanco C
    Patient Prefer Adherence; 2014; 8():1653-64. PubMed ID: 25525341
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Use of Disease-Modifying Treatments in Patients With Sickle Cell Disease.
    Newman TV; Yang J; Suh K; Jonassaint CR; Kane-Gill SL; Novelli EM
    JAMA Netw Open; 2023 Nov; 6(11):e2344546. PubMed ID: 37991760
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Impact of adherence to disease-modifying therapies on employment among veterans with multiple sclerosis.
    Rabadi MH; Just K; Xu C
    Disabil Rehabil; 2022 Aug; 44(16):4415-4420. PubMed ID: 33826431
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
    Hernandez L; Guo S; Toro-Diaz H; Carroll S; Syed Farooq SF
    J Med Econ; 2017 Mar; 20(3):228-238. PubMed ID: 27730845
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study.
    Leblanc S; Roux J; Tillaut H; Le Page E; Leray E
    Rev Neurol (Paris); 2021 Dec; 177(10):1250-1261. PubMed ID: 34253346
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cost sharing, benefit design, and adherence: the case of multiple sclerosis.
    Dor A; Lage MJ; Tarrants ML; Castelli-Haley J
    Adv Health Econ Health Serv Res; 2010; 22():175-93. PubMed ID: 20575233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.